Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:31.534Z.
Calculation as of: 2026-10-06T12:45:31.534Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Anteris Technologies Global Corp.
Market Cap
$734.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$719.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.33M
EV/EBITDA Ratio
2.84x
TTM Avg
4.78x
3Y Avg
5.46x
5Y Avg
7.57x
Market Cap
$767.46M
EV/EBITDA Ratio
N/A
TTM Avg
867.40x
3Y Avg
862.35x
5Y Avg
862.35x
Market Cap
$774.32M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.84x | 4.78x | 5.46x | 7.57x |
| Helus Pharma Inc. (HELP)vs › | $707.86M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | N/A | 867.40x | 862.35x | 862.35x |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 800.36x | 800.36x | 800.36x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
